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Performance of six diagnostic tests to screen for Chagas disease in blood banks and
prevalence of Trypanosoma cruzi infection among donors with inconclusive serology
screening based on the analysis of epidemiological variables 
Introduction
Chagas disease, originally described by the Brazilian researcher, Carlos Justiniano 
Ribeiro Chagas, in 1909 is one of the most widely distributed infectious diseases on the 
American continent, especially in Latin America, with approximately 25 million people living 
in risk areas. An estimated 10 million individuals are infected worldwide mostly in Latin 
America(1). The gradual control of natural transmission, mainly due to eradication of the vector 
in various countries where the disease is endemic, demonstrates the presence of secondary 
mechanisms of Chagas disease transmission, especially transfusional transmission(2-5). 
Scientific-technical progress in the fight against Chagas disease intensified in the 1980s. 
Thus, the intensification and standardization of sanitary surveillance measures by public and 
private blood centers in endemic countries - that began in the late 1960s in some Latin American 
countries - markedly contributed to a reduction in the frequency of non-negative serology for 
Trypanosoma cruzi among blood donors. While in the 1980s the predominance of seropositive 
donors in Latin America was 6%, this index dropped to 1.28 % by 2006(2). Concomitantly, 
transfusional transmission cases of Chagas disease have occurred in North America, Europe, 
Japan and Australia(1,4). Thus Chagas disease, which until recently had been seen as a serious 
Latin-American public health problem, has become a global public health threat. Especially with 
respect to the quality control of serological screening for Chagas disease among blood donors, 
the occurrence of false-positive results may lead to unnecessary disposal of blood units and 
consequently compromise the blood supply at blood centers. In addition, there are psychological 
and social consequences for the ineligible donor who believes that he has a stigmatized chronic 
disease. On the other hand, the occurrence of false-negative results may lead to transfusional 
transmission of Chagas disease. The greatest challenge currently encountered by blood banks 
is the frequent occurrence of inconclusive reactions, most of which are observed among non-
chagasic donors; this indicates failure in the specificity of screening tests(6-8).
In view of the lack of consensus in the international literature regarding the diagnostic 
test that correctly classifies a subject as seropositive or seronegative for Chagas disease (100% 
sensitivity and specificity), numerous researchers have proposed to improve the existing 
variations of the enzyme-linked immunosorbent assay (ELISA) - one technique recommended 
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by ANVISA, the Brazilian National Heath Surveillance Agency 
for screening donors - for example, by replacing natural T. cruzi 
antigens with recombinant antigen mixtures(9-12).
Several investigators have also proposed the inclusion of a 
clinical-epidemiological chart to assist in the investigation and 
definition of the true serological profile of ineligible donors, 
especially those presenting inconclusive reactions(7,13-15). This chart 
would include questions regarding the place and type of residence, a 
family history of Chagas disease, a history of contact with the vector, 
and a history of blood transfusions and surgery. This procedure has 
been shown to be effective in the differentiation between donors 
with or without T. cruzi infection when used simultaneously with 
serological and/or molecular biology tests(7,14), and will certainly be 
an important tool for the selection and exclusion of blood donors 
at blood centers in countries or geographic regions where Chagas 
disease is not endemic(15).
Thus, the goal of this work is to evaluate the efficacy of 
the blood culture test and five commercial tests (ELISA, IIF, 
HAI, c-ELISA, rec-ELISA) used in screening blood donors for 
Chagas disease, as well as to investigate the prevalence of T. cruzi 
infection among donors with inconclusive serology screening in 
respect to some epidemiological variables.
Methods
The target population of this study was stratified from 
a total of 95,990 donations based on a retrospective study of 
the database of the Uberaba Regional Blood Center (URBC) 
conducted between January 2000 and December 2005. From 269 
non-negative donors for Chagas disease (0.28%), 60 participants 
were randomly selected: Stratum II: 30 donors repeatedly positive 
using two screening tests (ELISA and IIF) and Stratum III: 30 
donors with inconclusive serology in the ELISA screening test 
or with discordant results in two tests. Additionally 30 donors 
with more than five negative donations at URBC over a six-year 
period (Stratum I) were included. This number was fixed due to the 
difficulty in contacting ineligible donors, especially those ineligible 
before 2003, which led to sample loss. The main reasons for this loss 
were changes of address and telephone number (30.4%), residing 
more than 120 km from Uberaba (26.4%), refusal to participate 
in the study (7%) and death (2%). All participants answered the 
following socio-epidemiological questionnaire: type of donor (first 
time, repeat), age (< 30: > 30 years), gender (male: female), living 
in an endemic region (yes: no), contact with the vector transmitting 
Chagas disease (yes: no) and a family history of Chagas disease 
(yes: no). A 30-mL sample of blood was drawn for each participant 
to perform five serological tests and a parasitological test.
In addition to the commercial ELISA test (ELISA cruzi® 
bioMérieux Diagnostica SA, Rio de Janeiro, Brazil), five 
other immunodiagnostic screening tests were performed in the 
ninety donors invited to participate in the study including: the 
commercial ELISA test (ELISA Chagatest® Wiener Lab, Rosario, 
Argentina); indirect immunofluorescence test (IIF - Imunocruzi®, 
bioMerieux Diagnostics SA, Rio de Janeiro, Brazil); indirect 
hemagglutination (IHA - Chagatest®, Wiener Lab, Rosario, 
Argentina); conventional ELISA (c-ELISA) which uses antigens 
derived from T. cruzi lysate and recombinant ELISA (rec-ELISA) 
using the recombinant antigens cytoplasmic repetitive antigen 
(CRA) and flagellar repetitive antigen (FRA) (EIE-Recombinant-
Chagas Bio-Manguinhos®, Bio-Manguinhos Laboratory, Oswaldo 
Cruz Foundation / FIOCRUZ, Brazilian Ministry of Health) and 
the blood culture test (HEMO), the only test that is known to be 
100% specific as it demonstrates the presence of the parasite.
Statistical Analysis
Due to the absence of a gold standard for the diagnosis of 
Chagas disease, a Bayesian latent class statistical model was 
considered in this particular case of six diagnostic tests, six covariates 
in the logit model(16,17) considering the assumption proposed by Hui 
& Walter(18), with different prevalence rates for chagasic infection 
but with a similar test performance among strata (SI: negative, 
SII: positive and SIII: inconclusive serology in the screening). The 
numerical Bayesian algorithm (Metropolis-Hastings algorithm) and 
the convergence evaluation were implemented in package R, which 
is freely available from www.r-project.org. The codes designed for 
the present study can be requested by e-mail from the authors. 
Ethical Aspects
The study was approved by the Ethics Committee of 
Universidade Federal do Triângulo Mineiro (UFTM - protocol # 
464) and all participants signed consent forms.
Results
Table 1 shows the results of the six tests under investigation 
for each of the three strata according to the result of serological 
screening at the time of donation. It was observed that 90% of 
donors with negative and 80% with inconclusive screening results 
were negative in all six tests investigated. Among the 30 donors 
with positive screening results, 96.6% had five or six positive 
results in the tests under investigation.
On analyzing the performance of tests without considering 
the covariates and the blood culture test, the general sensitivity 
between tests is very similar and higher than 97.63%. Two tests 
(IHA and IIF) were more specific with rates of 98.48% and 
98.52%, respectively (Table 2).
There was an increase in these rates when the covariates were 
taken into account, for example, all tests had sensitivities equal to or 
greater than 99.05% for donors older than 30 years and with a history 
of Chagas disease in the family; the ELISA, IIF and IHA tests had 
specificity rates above 99.05% for these same categories (Table 2).
Despite the very similar nominal values, the sensitivity 
rates of all serological tests (ELISA, IIF, IHA, c-ELISA and rec-
ELISA) were higher in over 30-year-old donors, females, who 
came from an endemic region, who had had contact with the 
vector and had a family history of Chagas disease. The IIF, IHA, 
c-ELISA and rec-ELISA tests were found to be more specific in 
repeat donors, over 30-year-old donors, females, who came from 
an endemic region, who had not had contact with the vector and 
had a family history of Chagas disease. In contrast, the ELISA 
test was more specific in first time donors who had had contact 
with the vector transmitting the disease (Table 2).
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Table 1 - Results of the tests under investigation according to the result at the time of screening test
Screening results
Tests under investigation Negative Positive Inconclusive
ELISA IIF IHA HEMO c-ELISA rec-ELISA n(%) n(%) n(%)
- - - - - - 27(90.0) 0 (0) 24 (80.0)
- - - - + - 2 (6.7) 0 (0) 5 (16.7)
+ - - - - - 1 (3.3) 0 (0) 1 (3.3)
+ + - - + - 0 (0) 1 (3.3) 0 (0)
+ + + - + + 0 (0) 17(56.7) 0 (0)
+ + + + + + 0 (0) 12 (40.0) 0 (0)
Total 30 (100) 30 (100) 30 (100)
ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofluorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: conventional 
ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)
Table 2 - Sensitivity (%) and specificity (%) of the six tests under investigation according to each level of the six 
covariates involved
Sensitivity (%)
Covariate ELISA IIF IHA HEMO c-ELISA rec-ELISAMean SD Mean SD Mean SD Mean SD Mean SD Mean SD
  General 97.76 0.88 97.64 0.93 97.70 0.85 58.07 0.80 97.63 0.93 97.76 0.90
  First time donor 98.23 0.70 98.19 0.73 98.23 0.66 57.75 0.80 98.14 0.73 98.27 0.70
  Repeat donor 97.17 1.11 96.94 1.20 97.01 1.11 58.38 0.79 96.98 1.17 97.11 1.15
  Age < 30 years 94.53 2.13 94.17 2.23 94.29 2.08 55.71 0.84 94.17 2.21 94.41 2.21
  Age > 30 years 99.10 0.37 99.06 0.39 99.09 0.36 60.38 0.82 99.05 0.39 99.12 0.37
  Male 95.21 1.86 94.84 2.02 94.98 1.84 58.57 0.79 94.96 1.93 95.15 1.89
  Female 98.96 0.43 98.94 0.44 98.96 0.40 59.57 0.80 98.90 0.45 98.98 0.43
Endemic region
  No 95.67 1.70 95.38 1.80 95.50 1.66 56.91 0.81 95.43 1.77 95.61 1.73
  Yes 98.85 0.47 98.81 0.49 98.83 0.45 59.22 0.80 98.78 0.49 98.87 0.47
Contact with vector
  No 96.54 1.35 96.31 1.44 96.39 1.33 56.33 0.82 96.29 1.44 96.50 1.39
  Yes 98.55 0.58 98.50 0.60 98.54 0.55 59.78 0.81 98.49 0.60 98.58 0.58
Family history
  No 94.44 2.16 94.03 2.31 94.20 2.13 56.01 0.83 94.21 2.23 94.30 2.26
  Yes 99.11 0.37 99.09 0.38 99.10 0.35 60.09 0.81 99.05 0.39 99.14 0.36
Specificity (%)
Covariate ELISA IIF IHA HEMO c-ELISA rec-ELISAMean SD Mean SD Mean SD Mean SD Mean SD Mean SD
  General 97.25 0.99 98.52 0.66 98.48 0.67 100 0 97.71 0.89 97.77 0.83
  First time donor 97.56 0.88 97.93 0.91 97.74 0.99 100 0 96.22 1.46 96.38 1.33
  Repeat donor 96.90 1.11 98.95 0.47 98.98 0.45 100 0 98.62 0.55 98.63 0.51
  Age < 30 years 92.18 2.84 95.51 2.00 95.48 2.02 100 0 95.53 1.73 95.63 1.61
  Age > 30 years 99.06 0.36 99.52 0.22 99.50 0.23 100 0 98.83 0.47 98.87 0.43
  Male 93.83 2.20 95.98 1.77 96.07 1.74 100 0 96.05 1.52 96.13 1.43
  Female 98.79 0.46 99.46 0.25 99.42 0.27 100 0 98.68 0.53 98.72 0.49
Endemic region
  No 94.28 2.05 96.72 1.45 96.69 1.47 100 0 95.88 1.57 95.93 1.50
  Yes 98.70 0.48 99.34 0.30 99.31 0.31 100 0 98.73 0.51 98.78 0.46
Contact with vector
  No 96.02 1.42 98.96 0.47 98.97 0.46 100 0 98.20 0.71 98.24 0.66
  Yes 98.11 0.69 97.90 0.93 97.76 0.98 100 0 97.09 1.13 97.17 1.04
Family history
  No 91.66 2.98 95.11 2.18 95.10 2.13 100 0 93.63 2.43 93.70 2.37
  Yes 99.12 0.35 99.56 0.21 99.54 0.22 100 0 99.19 0.34 99.22 0.30
SD: Standard Deviation; ELISA: enzyme-linked immunosorbent assay; IIF: indirect immunofluorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: 
conventional ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)
295Rev Bras Hematol Hemoter. 2012;34(4):292-7
Tests to screen for Chagas disease in blood banks
Table 3 - Prevalence rates (%) of Chagas disease for donors with 
inconclusive serology (Stratum III), according to the six covariates
 Prevalence
Covariate Mean SD
  General 13.30 0.22
  First time donor 15.22 0.25
  Repeat donor 11.59 0.20
  Age < 30 years 9.23 0.16
  Age > 30 years 18.79 0.30
  Male 9.90 0.17
  Female 17.64 0.28
Endemic region
  No 13.73 0.00
  Yes 15.71 0.00
Contact with vector
  No 11.98 0.00
  Yes 19.38 0.00
Family history
  No 9.55 0.00
  Yes 18.19 0.00
SD: Standard Deviation
Table 4 - Sensitivity (%) and specificity (%) of the five tests under 
investigation (not including the blood culture test) with parallel and serial 
testing schemes
 
 
 
Parallel Serial
Sensitivity Specificity Sensitivity Specificity
Mean SD Mean SD Mean SD Mean SD
ELISA + IIF 99.96 0.06 95.23 2.33 95.98 2.44 99.94 0.06
ELISA + IHA 99.96 0.07 95.13 2.38 95.94 2.50 99.94 0.07
ELISA + c-ELISA 99.96 0.06 94.61 2.48 95.97 2.41 99.93 0.07
ELISA + rec-ELISA 99.96 0.05 94.70 2.46 96.10 2.30 99.93 0.06
IIF + IHA 99.96 0.06 95.72 1.92 95.87 2.46 99.95 0.05
IIF + c-ELISA 99.96 0.07 95.20 2.06 95.91 2.40 99.94 0.05
IIF + rec-ELISA 99.96 0.05 95.29 2.05 96.04 2.32 99.94 0.05
IHA + c-ELISA 99.96 0.05 95.10 2.10 95.86 2.39 99.94 0.06
IHA + rec-ELISA 99.96 0.06 95.20 2.12 96.00 2.35 99.94 0.06
c-ELISA + rec-ELISA 99.96 0.05 94.68 2.25 96.03 2.27 99.93 0.07
ELISA + IIF + IHA 100 0.00 94.41 2.01 93.23 2.00 100 0.00
SD: Standard Deviation; ELISA: enzyme-linked immunosorbent assay; IIF: indirect 
immunofluorescence; IHA: indirect hemagglutination; HEMO: blood culture; c-ELISA: 
conventional ELISA using the Bio-Manguinhos kit; rec-ELISA (recombinant ELISA 
using the Bio-Manguinhos-FIOCRUZ kit and CRA and FRA antigens)
Table 5 - Negative predictive value (%) for three pairs of tests according to the parallel and serial testing schemes as well as epidemiological variables for 
donors with inconclusive serology screening
 
 
 
Parallel Serial
ELISA/c-ELISA ELISA/rec-ELISA c-ELISA/rec-ELISA ELISA/c-ELISA ELISA/rec-ELISA c-ELISA/rec-ELISA
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
  General 99.98 0.03 99.98 0.02 99.98 0.02 98.36 1.11 98.42 1.01 98.38 1.06
  First time donor 99.99 0.01 99.99 0.01 99.99 0.02 99.41 0.55 99.42 0.56 99.40 0.58
  Repeat donor 99.99 0.06 99.99 0.03 100 0.03 98.86 1.99 98.93 1.75 98.95 1.73
  Age < 30 years 99.63 0.58 99.67 0.43 99.66 0.45 89.82 5.67 90.17 5.42 90.01 5.45
  Age > 30 years 100 0.00 100 0.00 100 0.00 99.82 0.23 99.82 0.22 99.81 0.25
  Male 99.96 0.09 99.96 0.05 99.96 0.05 96.93 2.24 97.07 2.00 97.04 2.08
  Female 100 0.00 100 0.00 100 0.00 99.84 0.18 99.84 0.20 99.83 0.20
Endemic region
  No 99.93 0.10 99.94 0.08 99.94 0.08 97.11 1.70 97.19 1.65 97.20 1.50
  Yes 99.99 0.03 99.99 0.02 99.99 0.02 98.67 1.16 98.72 1.04 98.67 1.14
Contact with vector
  No 99.96 0.09 99.96 0.06 99.96 0.06 96.86 2.54 96.95 2.32 96.88 2.43
  Yes 100 0.00 100 0.00 100 0.00 99.82 0.19 99.83 0.18 99.82 0.19
Family history
  No 99.90 0.15 99.91 0.12 99.90 0.12 93.80 3.55 94.00 3.44 93.91 3.40
  Yes 100 0.01 100 0.00 100 0.00 99.77 0.33 99.78 0.27 99.77 0.33
SD: Standard Deviation
With respect to the prevalence of Chagas disease, an overall 
estimate of 13.30% was observed among donors with inconclusive 
serology in the screening test at the time of blood donation but this 
rate varied considerably depending on the covariates (Table 3).
When we consider testing in series which is suitable for 
situations that require greater specificity, where the diagnostic 
result is positive if all tests have positive results, we find a 
specificity of over 99.93% for all pairs of tests (not including 
the blood culture test) and 100% when we consider the ELISA, 
IIF, IHA tests together. While, the parallel scheme, indicated for 
urgent cases or for quality control as in blood banks, in which 
the set of tests is considered to be positive when at least one of 
the tests is positive, we found a sensitivity of over 99.96% for 
all pairs of tests (not including the blood culture test) and 100% 
when we consider ELISA, IIF, IHA tests together (Table 4).
The predictive values  (positive and negative) of all combinations 
of pairs of the five serological tests (ELISA, IIF, HAI, c-ELISA, rec-
ELISA) confirm the presence of T. cruzi infection with a probability of 
100% in the stratum of donors with positive serology screening when 
at least one of two tests has a positive result. In the stratum of donors 
with negative serology screening results, it is possible to affirm the 
absence of Chagas disease with a probability of 100% when at least 
one of two tests shows negative results. However, in the stratum of 
donors with inconclusive serology it is possible to confirm the absence 
of Chagas disease with a probability of 100% when the two tests have 
negative results depending on the epidemiological variables (Table 5).
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Discussion
In the present study, the general sensitivity rates were 
97.76%, 97.70% and 97.64% and the specificity was 97.25%, 
98.48% and 98.52% for the ELISA, IHA and IIF tests, 
respectively. These results show performances  similar to those 
found by Langui Junior et al.(19) but the sensitivity of IHA testing 
was higher in the present study. Studies on screening tests for 
Chagas disease reported sensitivity rates for the ELISA kit of 
bioMérieux ranging from 98.38% to 98.5% and specificity rates 
from 94.30% to 99.93%.(20,21) Sensitivity rates ranging from 
52.75% to 96.5% and specificity from 87% to 100%(22-24) have 
been described for IIF. Sensitivity rates from 98.5% to 100% 
and specificity between 99.69% and 100% have been reported 
for IHA.(19,20) Regarding the Bio-Manguinhos-FIOCRUZ kits, 
Gadelha et al.(22) found 100% sensitivity and specificity for the 
c-ELISA kit and sensitivity of 98.2% for the rec-ELISA kit.
Hence, it is essential to continually assess the performance 
of commercial tests that are still not totally efficacious. Failures in 
Chagas disease screening, may occur due to cross reactions with 
other parasites, in particular those of the trypanosomatid genus 
such as Leishmania which may have many genetic similarities 
with T. cruzi antigens and the same epitopes to bind to antibodies 
present in the sera of infected patients(20,25).
The publication of government directives numbers 153 and 
57 by ANVISA(26,27), made a single technique for the serological 
screening of blood donors for Chagas disease mandatory and 
that the blood bank must participate in external quality control 
programs. Thus it is important to seek screening methods by 
investigating specific T. cruzi antigens which minimize or exclude 
cross reactions.
Cross reactions in blood banks may be a cause of persistent 
serological ineligibility due to Chagas disease; this may correspond 
to up to 80% of inconclusive or false-positive serological results.
(8,11,20,28,29) Many studies report that inconclusive samples repeatedly 
showed negative results on using other tests.(11,26)
As, in this study, the estimated prevalence of Chagas disease 
was 13.30% in the stratum of donors with inconclusive serology 
at screening, 86.70% of donors probably do not have Chagas 
infection. This prevalence rate is well below the rate reported 
by Furuchó et al.(10) who observed that 20.5% of donors in the 
inconclusive serology group were positive for Chagas disease. 
In addition, on considering epidemiological variables in this 
stratum, the absence of Chagas’ infection can be affirmed with 
a probability of 100% when two tests give negative results in all 
pairs of serological tests.
Studies in epidemiology and statistics show that an association 
of two tests increases the quality of diagnosis, thereby reducing the 
number of false results. The simplest way of forming a set of tests 
is by  using in series or in parallel design(30) as used in this study.
Although there is no individual screening test for Chagas 
disease that has a sensitivity of 100%, sensitivity levels of 99.96% 
were found for several sets of tests in the parallel analysis. 
Additionally all pairs of tests (excluding HEMO) had specificities 
in series testing greater than 99.93% and the set formed by the 
ELISA, IIF and IHA tests had specificities of 100%, suggesting 
that this is the best alternative to confirm procedures. 
Studies report that the combination of epidemiological data 
with results of high performance testing allows a more accurate 
view of the serologic status of donors(10,11). To confirm these 
data, we find estimates for the sensitivity and specificity close to 
100% for certain epidemiological covariates suggesting that it is 
important to consider the inclusion of covariates in the structure 
of the model to evaluate the performance of the diagnostic tests.
In conclusion, commercial diagnostic tests (ELISA, IIF, 
HAI, c-ELISA, rec-ELISA) used to screen for Chagas disease, 
when used in pairs in serial testing schemes, proved to be an 
interesting alternative to confirm the procedure. In addition, 
epidemiological variables may contribute to improve the results 
of these tests and to clarify the true meaning of inconclusive 
serology screening. In search of a gold standard procedure 
and more reliable estimates, further studies are necessary with 
larger samples, clinical variables and further assume dependence 
between tests in statistical modeling.
Acknowledgements
We thank the Fundação Hemominas for providing the data 
and the Brazilian funding agencies Capes, ANVISA and CNPq 
for financial support. We thank the Laboratory Bio-Manguinhos, 
especially Antônio Gomes Pinto, Yara de Miranda Gomes, 
Edimilson Domingos da Silva and Marcelle Bral de Mello for 
providing the c-ELISA and rec-ELISA kits as well as processing 
of samples from the respective techniques. We also thank the 
anonymous reviewers for their comments and criticisms.
References
1. WHO 2010. First WHO report on neglected tropical diseases: Working 
to overcome the global impact of neglected tropical diseases (WHO/
HTM/NTD/2010.1) 2010 [cited 2012 March 20]; Available from: http://
whqlibdoc.who.int/publications/2010/9789241564090_eng.pdf
2. Organización Panamericana de la Salud. Estimación cuantitativa de la 
enfermedad de Chagas en las Americas. Geneva, Switzerland: OPAS; 
2006. 28p.
3. Souza HM. Mecanismos alternativos de transmissäo parenteral da 
Doença de Chagas. Rev Méd Minas Gerais. 1993; 3(2):93-5
4. Schmunis GA. Tripanosomíase Americana: seu impacto nas Américas e 
perspectivas de eliminação. In: Dias JC, Coura JR, organizadores. Clínica 
e terapêutica da doença de Chagas: uma abordagem prática para o clínico 
geral Rio de Janeiro: Fiocruz; 1997. p 11-24.
5. Dias JC. Elimination of Chagas disease transmission: perspectives Mem 
Inst Oswaldo Cruz. 2009;104(Suppl 1):41-5. 
6. Schmunis GA. Epidemiology of Chagas disease in non-endemic 
countries: the role of international migration. Mem Inst Oswaldo Cruz. 
2007; 102(Suppl 1):75-85.
7. Salles NA, Sabino EC, Cliquet MG, Eluf-Neto J, Mayer A, Almeida-Neto 
C, et al. Risk of exposure to Chagas disease among sero reactive Brazilian 
blood donors. Transfusion. 1996;36(11-12):969-73.
8. Melo AS, Lorena VM, Moraes AB, Pinto MB, Leão SC, Soares AK, et al. 
The prevalence of chagasic infection among blood donors in the state of 
Pernambuco, Brazil. Rev Bras Hematol Hemoter. 2009;31(2):69-73.
9. Reesink HW. European strategies against the parasite transfusion risk. 
Transfus Clin Biol. 2005;12(1):1-4.
297Rev Bras Hematol Hemoter. 2012;34(4):292-7
Tests to screen for Chagas disease in blood banks
10. Furuchó, CR, Umezawa, ES, Almeida, I, Freitas, VL, Bezerra, R, Nunes 
EV, et al. Inconclusive results in conventional serological screening 
for Chagas’ disease in blood banks: evaluation of cellular and humoral 
response. Trop Med Int Health. 2008;13(12):1527-33.
11. Ferreira-Silva MM, Pereira GA, Lages-Silva E, Moraes-Souza H. 
Socioepidemiological screening of serologically ineligible blood donors 
due to Chagas disease for the definition of inconclusive cases. Mem Inst 
Oswaldo Cruz. 2010;105(6):800-5.
12. Meira WS, Galvão LM, Gontijo ED, Machado-Coelho GL, Norris KA, 
Chiari E. Trypanosoma cruzi complement regulatory protein: a novel 
antigen for use in enzyme-linked immunosorbent assay for diagnosis of 
Chagas disease. J Clin Microbiol. 2002;40(10):3735-40.
13. Umezawa ES, Bastos SF, Coura JR, Levin MJ, Gonzalez A, Rangel-Aldao 
R, et al. An improved serodiagnostic test for Chagas disease employing 
a mixture of Trypanosoma cruzi recombinant antigens. Transfusion. 
2003;43(1):91-7.
14. Umezawa ES, Luquetti AO, Levitus G, Ponce C, Henriquez D, Revollo 
S, et al. Serodiagnosis of chronic and acute Chagas disease with 
Trypanosoma cruzi recombinant proteins: results of a collaborative study 
in six Latin American countries. J Clin Microbiol. 2004;42(1):449-52.
15. Cheng KY, Chang CD, Salbilla VA, Kirchhoff LV, Leiby DA, 
Schohetman, Chat DO. Immunoblot assay using recombinant antigens as 
a supplemental test to confirm the presence of antibodies to Trypanosoma 
cruzi. Clin Vaccine Immunol. 2007;14(4):355-61. 
16. Hadgu A, Qu Y. A Biomedical application of latent class models with 
random effects. Appl Stat. 1998;47(4):603-16.
17. Martinez EZ, Louzada-Neto F, Achcar JA, Syrjänen KJ, Derchain 
SF, Gontijo RC, et al. Bayesian Estimation of performance measures 
of screening tests in the presence of covariates: an absence of a gold 
standard. Braz J Probab Stat. 2009;23(1):68-81.
18. Hui SL, Walter SD. Estimating the error rates of diagnostic tests. 
Biometrics. 1980;36(1):167-71.
19. Langhi Junior DM, Bordin JO, Castelo A, Walter SD, Moraes-Souza H, 
Stumpf RJ. The application of latent class analysis for diagnostic test 
validation of chronic trypanosoma cruzi infection in blood donors. Braz 
J Infect Dis. 2002;6(40):181-7.
20. Flores-Chávez M, Cruz I, Rodríguez M, Nieto J, Franco E, Gárate T, et al. 
Comparación de técnicas serológicas convencionales y no convencionales 
para El diagnóstico de la enfermedad de Chagas importada en España. 
Enferm Infecc Microbiol Clin 2010;28(5):284-93. Spanish.
21. Praast G, Herzogenrath J, Bernhardt S, Christ H, Sickinger E. Evaluation 
of the Abbott ARCHITECT Chagas prototype assay. Diagn Microbiol 
Infect Dis. 2011;69(1):74-81.
22. Gadelha AA, Verçosa AF, Lorena VM, Nakazawa M, Carvalho AB, 
Souza WV, et al. Chagas disease diagnosis: comparative analysis of 
recombinant ELISA with conventional ELISA and the haemagglutination 
test. Vox Sang. 2003;85(3):165-70.
23. Pirard M, Iihoshi N, Boelaert M, Basanta P, López F, der Stuyft P. The 
validity of serologic tests for Trypanosoma cruzi and the effectiveness of 
transfusional screening strategies in a hyperendemic region. Transfusion. 
2005;45(4):554-61. 
24. Lunardelli A, Borges FP, Mello KF, Zeferino AS. Soroprevalência da 
doença de Chagas em candidatos a doadores de sangue. Rev Bras Anal 
Clin. 2007;39(2):139-41.
25. Brasil PE, Castro L, Hasslocher-Moreno Am, Sangenis L, Braga JU. 
Elisa versus PCR for diagnosis of chronic Chagas disease: Systematic 
review and meta-analysis. BMC Infect Dis. 2010;10:337-53.
26. ANVISA. Agência Nacional de Vigilância Sanitária. Resolução 
RDC nº 153, de 14 de junho de 2004. Publicada no Diário Oficial da 
união de 24 de junho de 2004. [citado 2001 Out 11]. Available from: 
http://e-legis.anvisa.gov.br/leisref/public/showAct. php?id=11662. 
27. ANVISA. Agência Nacional de Vigilância Sanitária. Resolução RDC nº 
57, de 17 de outubro de 2010. Publicada no Diário Oficial da União em 
16 de dezembro de 2010. [citado 2011 Out 11]. Available from: http://
portal.anvisa.gov.br/. 
28. Leiby DA, Herron RM Jr, Garratty G, Herwaldt BL. Trypanosoma cruzi 
parasitemia in: US Blood donors with serologic evidence of infection. J 
Infect Dis. 2008;198(4):609-13
29. Sabino EC, Salles NA, Sarr M, Barreto AM, Oikawa M, Oliveira CD, 
Leao SC, Carneiro-Proietti AB, Custer B, Busch MP; NHLBI Retrovirus 
Epidemiology Donor Study-II (REDS-II), International Component. 
Enhanced classification of Chagas serologic results and epidemiologic 
characteristics of seropositive donors at three large blood centers in 
Brazil. Transfusion. 2010;50(12):2628-37.
30. Arango HG. Bioestatística: teórica e computacional. 2nd ed. Rio de 
Janeiro: Guanabara Koogan; 2005.
xxx
